Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults

NCT07008144 | Not Yet Recruiting

• 1 other identifier: CSAPG-73
• Study Type: interventional
• Target: 5,954
• Locations: 1 country
• Sites: 2

Brief Summary

The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount (more than 0.125 mg/day). The main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg/day (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.

Conditions

Drug-Related Side Effects and Adverse Reaction; Digoxin Overdose

Keywords

digoxin; deprescription; Beers; computerized alerts; geriatrics; Elderly Hospitalized Patients

Outcome Measures

Primary Outcomes (1)

• Proportion of elderly inpatients receiving inappropriate digoxin doses

  Proportion of patients aged 65 and older who are prescribed digoxin at a dose higher than 0.125 mg/day during hospitalization. The outcome compares this proportion between the pre-intervention and post-intervention periods to evaluate the effectiveness of a computerized alert integrated into the electronic medical record system (MIRA).

  From baseline to hospital discharge, as much 3 months

Study Arms (2)

Before intervention

NO INTERVENTION

In this group, the outcome will be measured before the intervention is implemented at the center

Post intervention

EXPERIMENTAL

In this group, the outcome will be measured after the intervention is implemented at the center

Other: Digoxin alarm

Interventions

Digoxin alarm OTHER

A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.

Post intervention

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Men and women over 64 years of age.
• Hospitalized in inpatient wards of the study centers during the study period.

You may not qualify if:

• Pacients under 64 years old
• Patients without complete data available

Sponsors & Collaborators

• Consorci Sanitari de l'Alt Penedès i Garraf: lead

Study Sites (2)

Consorci Sanitari Alt Penedès-Garraf-Hospital de Vilafranca

Vilafranca del Penedès, Barcelona, 08720, Spain

Location

Consorci Sanitari Alt Penedès-Garraf Hospital Sant Camil

Barcelona, Spain, 08810, Spain

Location

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Study Officials

• Alejandro Rodríguez Molinero

  Consorci Sanitari de l'Alt Penedès i Garraf

  STUDY DIRECTOR

Central Study Contacts

Beatriz P Ortiz Naranjo

CONTACT

+34606820268; beatrizortiznaranjo@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 26, 2025
• First Posted: June 6, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): November 30, 2026
• Last Updated: December 2, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After publication of main results of the study.
• Access Criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

Locations

ES (2)